» Articles » PMID: 24619583

The Application of Tissue-engineered Preputial Matrix and Fibrin Sealant for Urethral Reconstruction in Rabbit Model

Overview
Publisher Springer
Specialty Nephrology
Date 2014 Mar 13
PMID 24619583
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To introduce the role of fibrin sealant and preputial acellular matrix (PAM) as a new source of inert collagen matrix for urethral reconstruction.

Methods: A ventral urethral segmental defect was created in 24 male rabbits divided into four groups. In group 1 (G1), urethrotomy was closed in layers. In group 2 (G2), closure was followed by applying fibrin sealant. In groups 3 (G3) and 4 (G4), urethroplasty was performed with a patch graft of PAM, and in G4, fibrin sealant was also applied. Serial urethrography was performed before and after the operation. Then, the animals were euthanized, and their urethra was excised 1, 3, and 9 months postoperatively for further electron microscopic examination, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) technique, and immunohistochemical (IHC) staining with CD34, CD31, desmin, SMA, and α-actin.

Results: In G1 and G2, the fistula repair failed in all the time points. In G3 and G4, serial urethrography confirmed the maintenance of a wide urethral caliber without signs of strictures or extravasations. Satisfactory vascularity was observed in G3 and G4 during the whole study, which was more significant in G4 after 9 months of follow-up. The presence of a complete transitional cell layer was confirmed over the graft in G3 and G4 in all time points. IHC staining confirmed the effectiveness of fistula repair in G3 and G4, 3 months postoperatively.

Conclusion: This rabbit model showed that PAM combined with fibrin sealant may herald a reliable option for repairing segmental urethral defects.

Citing Articles

Tissue Engineering and Regenerative Medicine in Pediatric Urology: Urethral and Urinary Bladder Reconstruction.

Casarin M, Morlacco A, Dal Moro F Int J Mol Sci. 2022; 23(12).

PMID: 35742803 PMC: 9224288. DOI: 10.3390/ijms23126360.


Quality of Reporting in Preclinical Urethral Tissue Engineering Studies: A Systematic Review to Assess Adherence to the ARRIVE Guidelines.

Abbas T, Elawad A, S A, Pennisi C Animals (Basel). 2021; 11(8).

PMID: 34438913 PMC: 8388767. DOI: 10.3390/ani11082456.


Local tissue reaction and histopathological characteristics of three different bulking agents: a rabbit model.

Sabetkish S, Mohseni M, Sabetkish N, Kajbafzadeh A Int Braz J Urol. 2020; 47(2):322-332.

PMID: 33146977 PMC: 7857764. DOI: 10.1590/S1677-5538.IBJU.2020.0171.


The current state of tissue engineering in the management of hypospadias.

Chan Y, Bury M, Yura E, Hofer M, Cheng E, Sharma A Nat Rev Urol. 2020; 17(3):162-175.

PMID: 32024995 DOI: 10.1038/s41585-020-0281-4.


Development of a Chitosan-Vaseline Gauze Dressing with Wound-Healing Properties in Murine Models.

Fang Q, Wang X, Zhao W, Shi B, Lou D, Chen C Am J Trop Med Hyg. 2019; 102(2):468-475.

PMID: 31802727 PMC: 7008328. DOI: 10.4269/ajtmh.19-0387.


References
1.
Palminteri E, Berdondini E, Colombo F, Austoni E . Small intestinal submucosa (SIS) graft urethroplasty: short-term results. Eur Urol. 2007; 51(6):1695-701. DOI: 10.1016/j.eururo.2006.12.016. View

2.
Manzoni G, Bracka A, Palminteri E, Marrocco G . Hypospadias surgery: when, what and by whom?. BJU Int. 2004; 94(8):1188-95. DOI: 10.1046/j.1464-410x.2004.05128.x. View

3.
Raya-Rivera A, Esquiliano D, Yoo J, Lopez-Bayghen E, Soker S, Atala A . Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet. 2011; 377(9772):1175-82. PMC: 4005887. DOI: 10.1016/S0140-6736(10)62354-9. View

4.
Bracka A . Buccal mucosa: good but not perfect. J Urol. 2011; 185(3):777-8. DOI: 10.1016/j.juro.2010.12.015. View

5.
Aulagne M, Harper L, de Napoli-Cocci S, Bondonny J, Dobremez E . Long-term outcome of severe hypospadias. J Pediatr Urol. 2010; 6(5):469-72. DOI: 10.1016/j.jpurol.2009.12.005. View